Maynard Um
-
-
-
-
-
-
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
-
-
-
-
-
-
Stifel on Dyne Therapeutics Inc. (DYN): 'Longer-term Data At MDA Support DYNE-251's Strong DMD Profile'
-
-
-
-
-
-
-
Dynegy (DYN) Tops Q4 EPS by 1c
-
-
-
-
-
-
-
Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN)
-
-
-
-
-
-
-
Oppenheimer Downgrades Dyne Therapeutics (DYN) to Perform
-
-
-
-
-
-
-
Dyne Therapeutics (DYN) PT Lowered to $36 at Stifel
-
-
-
-
-
-
-
Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN) Following FDA Update
-
415,785 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

